Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Citoplurikin; IRX-2

Latest Information Update: 13 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IRX Therapeutics
  • Developer Brooklyn ImmunoTherapeutics; H. Lee Moffitt Cancer Center and Research Institute; Providence Health & Services; University of Southern California
  • Class Antineoplastics; Cytokines
  • Mechanism of Action Dendritic cell stimulants; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cervical intraepithelial neoplasia; Head and neck cancer; Vulvar intraepithelial neoplasia
  • Phase I Breast cancer; Solid tumours

Most Recent Events

  • 28 Aug 2019 IRX Therapeutics withdraws a phase I trial for Oropharyngeal-cancer (Neo-adjuvant therapy, combination therapy, Late-stage disease) in USA prior to enrollment (NCT03575234)
  • 31 May 2019 Pharmacodynamics data from preclinical studies in Head and neck cancer presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 05 Feb 2019 Phase-I clinical trials in Solid tumours (Combination therapy, Second-line therapy or greater) in USA (SC) (NCT03758781)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top